Traws Pharma (NASDAQ:TRAW) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Traws Pharma (NASDAQ:TRAW) from a hold rating to a sell rating in a report issued on Saturday morning.

Several other research firms also recently commented on TRAW. HC Wainwright started coverage on shares of Traws Pharma in a report on Wednesday. They issued a “buy” rating and a $8.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Traws Pharma in a research note on Monday, December 1st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.00.

Traws Pharma Trading Down 3.0%

TRAW opened at $2.29 on Friday. Traws Pharma has a 12-month low of $0.97 and a 12-month high of $19.44. The company’s 50 day moving average is $2.40 and its 200 day moving average is $1.88. The company has a market cap of $18.30 million, a price-to-earnings ratio of 0.02 and a beta of 1.74.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($9.16) by $8.82. Traws Pharma had a negative return on equity of 2,883.04% and a net margin of 3,028.25%.

Hedge Funds Weigh In On Traws Pharma

Several institutional investors have recently bought and sold shares of TRAW. Vestal Point Capital LP grew its stake in shares of Traws Pharma by 133.3% in the 1st quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock worth $402,000 after buying an additional 100,000 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Traws Pharma during the 1st quarter valued at about $759,000. Finally, Two Sigma Investments LP lifted its holdings in shares of Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares during the last quarter. Institutional investors own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.